HS-201 (Solid Malignancies) - Clinical Trial
Email to Participate
jessica.a.morris@duke.edu
What is the Purpose of this Study?
We are doing this study to see how much of the study drug (an imaging agent called HS-201) is needed to mark cancer cells and help doctors to see cancer during and after surgery.
What is the Condition Being Studied?
Solid Malignancies (cells with cancer)
Who Can Participate in the Study?
-Adults
-Diagnosis of a solid malignancy
-Planned surgical removal or biopsy of cancerous cells
Age Group
Adults
What is Involved?
If you choose to join this study you will:
-Have the the study drug (HS-201) given into your vein the day before your surgery.
-Have a small amount of tissue taken out during your surgery
One month after your surgery you will:
-Have a physical exam
-Answer questions about how you are feeling after your surgery
-Give blood samples
Study Details
Full Title
A PHASE I STUDY OF HS-201, AN HSP90 INHIBITOR-LINKED VERTEPORFIN FOR DETECTION OF SOLID MALIGNANCIES
Principal Investigator
H. Kim Lyerly
Protocol Number
IRB:
PRO00102188
NCT:
NCT03906643
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate